News & Events

• March 19, 2019
  

  The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients

• March 18, 2019
  

  C-Path President and CEO, Board Director Selected to Serve on Esteemed National Academies of Sciences, Engineering and Medicine Committee

  C-Path President and CEO Martha Brumfield, PhD, and C-Path Board Director Alastair J. Wood, MD, FRCP, have both been selected to the serve on the National Academy Consensus Committee examining Mutual Recognition Agreements in the Regulation of Medicines under The National Academies of Sciences, Engineering and Medicine. Dr. Wood will serve as chair. An ad...
• March 17, 2019
  

  Increasing Efficiency, Safety, and Speed in Clinical Trials for Neurodegenerative Diseases | Alzheimer’s Drug Discovery Foundation Conference, Long Beach, CA

• March 14, 2019
  

  C-Path, FNIH Announce Clinical Development User’s Guide for Kidney Safety Biomarkers

      TUCSON, Ariz., March 14, 2019 — The Critical Path Institute’s (C-Path) Predictive Safety Testing Consortium (PSTC) today announced availability of the User’s Guide: Kidney Safety Composite Measure Biomarker for Use in Clinical Development. Authored by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Kidney Safety Biomarker Project Team and PSTC’s...
• March 13, 2019 - March 16, 2019
  

  Poster presentation at the American Society for Clinical Pharmacology & Therapeutics Meeting, March 13-16, 2019, Washington, DC